| Abacavir/ dolutegravir/ lamivudine |
ViiV Healthcare Company |
6/7/2023 |
|
| Abatacept |
BMS |
2/14/2017 |
|
| Acetaminophen |
Mallinckrodt |
7/11/2016 |
|
| Afatinib |
Boehringer Ingelheim Pharmaceuticals, Inc. |
3/8/2022 |
|
| Aflibercept |
Regeneron Pharmaceuticals |
10/18/2022 |
|
| Albuterol |
GlaxoSmithKline |
8/27/2008 |
|
| Alfuzosin |
Sanofi Aventis |
9/7/2010 |
|
| Aliskiren |
Noden Pharma DAC |
10/3/2017 |
|
| Almotriptan |
Johnson & Johnson Pharmaceutical Research & Development |
1/13/2009 |
|
| Amphetamine |
Shire |
8/18/2019 |
|
| Anastrozole |
AstraZeneca |
11/14/2007 |
|
| Apremilast |
Amgen Inc. |
4/22/2024 |
|
| Aripiprazole |
Otsuka |
11/14/2007 |
|
| Asenapine |
Forest Labs |
3/3/2015 |
|
| Atazanavir |
BMS |
6/23/2015 |
|
| Atezolizumab |
Genentech |
9/22/2020 |
|
| Axitinib |
Pfizer, Inc. |
7/2/2024 |
|
| Azelastine/Fluticasone and Azelastine |
Meda Pharmaceuticals |
3/23/2015 |
|
| Bendamustine |
Cephalon |
5/24/2012 |
|
| Bezlotoxumab |
Merck Sharpe and Dohme |
5/12/2023 |
|
| Bicalutamide |
AstraZeneca |
9/19/2008 |
|
| Bivalirudin |
The Medicines Company |
6/17/2009 |
|
| Blinatumomab |
Amgen |
6/13/2023 |
|
| Bosutinib |
PF Prism, C.V. |
9/7/ 2023 |
|
| Bortezomib |
Millennium Pharmaceuticals |
8/14/2015 |
|
| Brentuximab vedotin |
Seagen, Inc. |
11/18/2022 |
|
| Brexpiprazole |
Otsuka Pharmaceutical Development & Commercialization |
5/2/2024 |
|
| Budesonide/Formoterol |
AstraZeneca |
1/25/2017 |
|
| Cabazitaxel |
Sanofi Aventis |
5/18/2017 |
|
| Calcipotriene/Betamethasone |
Leo Pharma |
7/15/2019 |
|
| Canagliflozin |
Janssen Pharmaceuticals, Inc. |
12/9/2024 |
|
| Candesartan |
AstraZeneca Pharmaceuticals LP |
7/20/2009 |
|
| Capecitabine |
Hoffman-La Roche, Inc. |
8/28/2013 |
|
| Caspofungin |
Merck & Co., Inc. |
4/15/2008 |
|
| Cetirizine |
Nicox Ophthalmics |
8/29/16 |
|
| Clopidogrel |
Sanofi Aventis |
1/20/2011 |
|
| Cobimetinib |
Genentech, Inc. |
7/19/2022 |
|
| Colesevelam |
Daiichi Sankyo Pharma |
2/17/2009 |
|
| Crisaborole |
Pfizer |
2/21/2020 |
|
| Cysteamine |
Horizon |
12/12/2017 |
|
| Dabigatran |
Boehringer Ingelheim Pharmaceuticals, Inc. |
2/12/2021 |
|
| Dabrafenib |
Novartis |
2/9/2023 |
|
| Dapagliflozin |
AstraZeneca AB |
5/30/2024 |
|
| Darunavir |
Tibotec |
6/7/2011 |
|
| Deutetrabenazine |
Teva Branded Pharmaceutical Products |
5/5/2021 |
/
|
| Dexmedetomidine |
Hospira |
3/12/2013 |
|
| Difluprednate |
Alcon |
3/21/2013 |
|
| Docetaxel |
Sanofi Aventis |
3/17/2010 |
|
| Dulaglutide |
Eli Lilly and Company |
October 4, 2022 |
|
| Duloxetine |
Eli Lilly |
7/2/2012 |
|
| Efavirenz |
BMS |
1/29/2013 |
|
| Eltrombopag |
Novartis |
8/14/2015 |
|
| Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide |
Gilead Sciences, Incorporated |
9/13/2021 |
|
| Empagliflozin/Empagliflozin and Metformin hydrochloride |
Boehringer Ingelheim Pharmaceuticals |
6/9/2023 |
|
| Entecavir |
BMS |
12/5/2013 |
|
| Eplerenone |
Pfizer |
10/24/2007 |
|
| Eribulin Mesylate |
Eisai, Inc. |
8/9/2022 |
|
| Erlotinib |
OSI Pharmaceuticals |
3/18/2015 |
|
| Esomeprazole |
AstraZeneca LP |
5/1/2009 |
|
| Eszopiclone |
Sunovion |
6/29/2012 |
|
| Etravirine |
Janssen |
6/21/2018 |
|
| Everolimus |
Novartis |
7/10/2012 |
|
| Exenatide |
AstraZeneca |
4/1/2021 |
|
| Ezetimibe |
Schering Corporation |
2/14/2008 |
|
| Famciclovir |
Novartis |
9/21/2009 |
|
| Fenfluramine hydrochloride |
Zogenix, Inc |
3/23/2022 |
|
| Ferric Oxyhydroxide |
Vifor Fresenius Medical Care Renal Pharma France |
6/1/2021 |
|
| Fesoterodine |
Pfizer |
6/3/2021 |
|
| Fidaxomicin |
Cubist |
12/13/2019 |
|
| Finafloxacin |
Alcon |
8/25/2014 |
|
|
Fingolimod
|
Novartis |
4/16/2018 |
|
| Fluticasone & Fluticasone/Salmeterol |
Teva Pharmaceutical Industries Ltd. |
6/10/2021 |
|
| Fluticasone furoate vilanterol trifenatate |
GlaxoSmithKline |
4/26/2023 |
|
| Fosamprenavir |
ViiV Healthcare |
1/10/2012 |
|
| Fosaprepitant |
Merck |
3/23/2018 |
|
| Fulvestrant |
AstraZeneca |
2/1/2011 |
|
| Gatifloxacin |
Allergan |
5/19/2009 |
|
| Glecaprevir/Pibrentasvir |
AbbVie, Inc. |
5/18/2021 |
|
| Guanfacine |
Shire |
10/17/2014 |
|
|
Halobetasol
|
Mayne Pharma LLC |
5/21/2021 |
|
| Ibrutinib |
Pharmacyclics |
8/8/2022 |
|
| Ipilimumab |
BMS |
7/20/17 |
|
| Isavuconazonium sulfate |
Astellas Pharma US Inc. |
11/29/2023 |
|
| Ixabepilone |
BMS |
4/5/2011 |
|
Ivabradine |
Amgen |
3/30/2019 |
|
| Lanadelumab |
Takeda Pharmaceuticals U.S.A., Inc. |
12/20/2022 |
|
| Lansoprazole |
Tap Pharmaceutical Products, Inc. |
7/15/2008 |
|
| Lenvatinib Mesylate |
Eisai Inc. |
4/1/2024 |
|
| Levetiracetam |
UCB, Inc. |
6/3/2008 |
|
| Levocetirizine |
UCB, Inc. |
8/25/2009 |
|
| Linagliptin/Linagliptin and metformin hydrochloride |
Boehringer Ingelheim Pharmaceuticals |
6/9/2023 |
|
| Liraglutide |
Novo Nordisk |
5/1/2019 |
|
| Lisdexamfetamine |
Takeda Pharmaceuticals USA, Inc. |
7/27/2021 |
|
| Loteprednol/Tobramycin |
Bausch & Lomb |
12/28/2010 |
|
| Lopinavir/Ritonavir |
Abbott Laboratories |
3/7/2008 |
|
| Lumacaftor/Ivacaftor |
Vertex Pharmaceuticals Inc. |
12/11/2024 |
|
| Lurasidone |
Sunovion |
12/20/2016 |
|
| Lutetium Lu 177 dotatate |
Advanced Accelerator Applications |
4/19/2024 |
|
| Maraviroc |
ViiV Healthcare Co |
7/29/2020 |
|
| Memantine |
Forest Labs |
6/16/2014 |
|
Methylphenidate |
Rhodes Pharmaceuticals |
3/15/2019 |
|
| Micafungin |
Astellas |
11/14/2019 |
|
| Mirabegron |
Astellas Pharma Global Development, Inc. |
3/1/2021 |
|
| Mometasone/formoterol |
Merck |
6/24/2019 |
|
| Nilotinib |
Novartis |
3/20/2018 |
|
| Nintedanib |
Boehringer Ingelheim Pharmaceuticals |
10/6/2023 |
|
| Nitric Oxide |
INO Therapeutics |
11/2/2010 |
|
Nivolumab |
|
2/2/2023 |
|
| Olmesartan |
Daiichi Sankyo |
10/7/2009 |
|
| Olopatadine |
Alcon Research, Ltd. |
8/12/2009 |
|
| Olopatadine |
Alcon Research, Ltd. |
12/16/2014 |
|
| Paclitaxel |
Abraxis |
11/8/2019 |
|
| Paliperidone |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
1/5/2011 |
|
| Palonosetron |
Helsinn |
4/10/2014 |
|
| Pantoprazole |
Wyeth Pharmaceuticals, Inc. |
2/17/2009 |
|
| Pemetrexed |
Eli Lilly |
12/3/2010 |
|
| Phenylephrine/Ketorolac |
Omeros |
12/6/2017 |
|
Pitavastatin |
Kowa Research Institute] |
3/30/2019 |
|
| Pomalidomide |
Celgene Corporation |
10/16/2020 |
|
| Prasugrel |
Eli Lilly |
5/23/16 |
|
| Quetiapine |
AstraZeneca Pharmaceuticals LP |
1/23/2009 |
|
| Rabeprazole |
Eisai |
12/4/2012 |
|
| Raltegravir |
Merck |
8/14/2017 |
|
| Remdesivir |
Gilead Sciences, Inc. |
January 23, 2024 |
|
| Rilpivirine |
Janssen Products, LP. |
1/18/2024 |
|
| Risedronate |
Procter & Gamble Pharmaceuticals, Inc. |
4/24/2009 |
|
| Rivaroxaban |
Janssen Pharmaceuticals, Inc. |
11/23/2021 |
|
| Rizatriptan |
Merck |
9/20/2011 |
|
| Rocuronium |
Organon, Inc. |
4/3/2008 |
|
| Rosuvastatin |
AstraZeneca Pharmaceuticals LP |
7/7/2009 |
|
| Rufinamide |
Eisai |
1/13/2015 |
|
| Ruxolitinib |
Incyte Corporation |
12/1/2022 |
|
| Sacubitril/Valsartan |
Novartis
|
9/26/2019 |
|
| Sapropterin |
BioMarin |
3/13/2014 |
|
| Saquinavir |
Hoffman-La Roche, Inc. |
10/26/2010 |
|
| Sildenafil |
Pfizer |
2/9/2012 |
|
| Sitagliptin |
Merck Sharp & Dohme Corp. |
10/30/2020 |
|
| Sofosbuvir |
Gilead Sciences, Inc. |
7/23/2019 |
|
| Sofosbuvir/Ledipasvir |
Gilead Sciences, Inc. |
7/23/2019 |
|
Sofosbuvir/Velpatasvir |
Gilead Sciences, Inc. |
5/13/2021 |
|
| Solifenacin |
Astellas |
7/20/2017 |
|
| Sugammadex |
Merck, Sharp & Dohme LLC (Merck) |
12/9/2024 |
|
| Sumatriptan/Naproxen |
GlaxoSmithKline/Pernix |
4/16/2015 |
|
| Tadalafil |
Eli Lilly |
11/16/2017 |
|
| Tamsulosin |
Boehringer Ingelheim |
9/17/2009 |
|
| Tapentadol |
Collegium Pharmaceutical Inc. |
June 11, 2024 |
|
| Tavaborole |
Anacor |
7/18/2018 |
|
| Tbo-filgrastim |
Sicor |
7/18/2018 |
|
| Technetium Tc99 sestamibi |
BMS |
1/11/2008 |
|
| Teduglutide |
Shire – NPS Pharmaceuticals |
3/7/2019 |
|
| Temsirolimus |
Pfizer |
2/28/2012 |
|
| Tenofovir |
Gilead Sciences, Inc. |
9/6/2011 |
|
Tenofovir |
Gilead Sciences, Inc. |
11/15/2018 |
|
| Teriflunomide |
Sanofi Aventis |
3/31/2021 |
|
| Ticagrelor |
AstraZeneca |
4/8/2022 |
|
| Tiotropium |
Boehringer Ingelheim Pharmaceuticals, Inc. |
12/14/16 |
|
| Tipranavir |
Boehringer Ingelheim Pharmaceuticals, Inc. |
3/7/2008 |
|
| Tocilizumab |
Genentech/Hoffmann-La Roche |
7/18/2018 |
|
| Tofacitinib NEW |
Pfizer, Inc |
02/19/2025 |
|
| Topiramate |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
7/24/2008 |
|
| Trabectedin |
Janssen |
6/12/2018 |
|
| Trametinib |
Novartis |
2/9/2023 |
|
| Valacyclovir |
GlaxoSmithKline |
2/28/2008 |
|
| Valganciclovir |
Hoffman-La Roche Inc. |
7/24/2008 |
|
| Valproate |
Abbott |
12/14/2007 |
|
Varenicline |
Pfizer |
11/15/2018 |
|
| Vigabatrin |
Lundbeck |
10/3/2013 |
|
| Vilazodone |
Allergan |
1/21/2020 |
|
| Vortioxetine |
Takeda Pharmaceuticals USA Inc. |
8/21/2023 |
|
| Zoledronic acid |
Novartis |
12/21/2007 |
|
Source
Clinical :: Oncology :: Nuclear :: Geriatric :: Regulatory :: Technology :: Consulting
"My passion is helping businesses, small and large, perform at their best." - Felicia Udoji-Eddings, Pharm.D.
Dr. Felicia Udoji-Eddings is the Founder and CEO of The Health Pals Company, a vertically integrated Healthcare System. As an experienced Clinical Pharmacy Leader, Pharmacy Consultant, Healthcare Executive, and Licensed Pharmacy Practitioner with deep backgrounds in Information Technology (IT), Scientific Research, and Business Management. Dr. Udoji-Eddings has a strong track record of exceptional performance in different business environments. A skilled Business Strategist, Dr. Udoji-Eddings has tackled complex problems and helped several organizations refocus their strategy in tough economic times. As a highly motivated and proactive individual, Felicia enjoys working with teams, in various capacities, to facilitate positive outcomes.